Prelude clinical performance is consistent with the NIPS literature, and is achieved without a FF failure threshold. Our results demonstrate that Prelude achieves high accuracy and a low test-failure rate in a large general obstetric population.
OBJECTIVE:
To estimate race/ethnic group correction factors for firsttrimester expanded Early-Onset Preeclampsia and Down syndrome screening markers. STUDY DESIGN: Maternal serum data from 12,876 patients in the United States including 2538 with mean arterial pressure (MAP) measurements and 1577 with uterine Artery Doppler pulsatility index (UtAD-PI) was analyzed. Weight-adjusted MoM values using the gestational age specific medians in the Caucasian group were calculated for maternal serum free beta hCG, pregnancy associated plasma protein A (PAPP-A), Alpha-Fetoprotein (AFP) African American patients were significantly higher for all serum analytes tested. In addition, UtAD-PI was significantly increased in this group. Asian patients demonstrated significantly higher Inhibin while Asian Indian patients were significantly higher for both Inhibin and PlGF. Hispanic patients were low for Free beta hCG and AFP but were slightly higher for Inhibin and UtAD-PI. CONCLUSION: All first trimester biochemical markers for Early Onset Preeclampsia and Down syndrome screening vary based on maternal race/ethnicity. UtAD-PI similarly varies based on race/ethnicity but no statistically significant change in MAP was observed in any ethnic group. Adjustments for each marker except MAP are indicated.
925 Non-reportable cell-free DNA: patient preferences, utility of repeat draw, and outcomes A NR result for a microdeletion but negative testing for above chromosomes were excluded. The primary outcome was aneuploidy or microarray abnormality on prenatal or postnatal genetic testing. Secondary outcomes evaluated were maternal characteristics, testing laboratory and methodology, and pregnancy and neonatal outcomes. Statistical analysis was performed utilizing Student's t-test and Fisher's exact test. RESULTS: Forty-six patients had NR cfDNA results, of which 31 (67.4%) had low fetal fraction (FF). Mean maternal age was 34.2 AE 4.9 years, and median gestational age at initial blood draw was 10.4 weeks (IQR 10.1 e 11.6). Median body mass index (BMI) was 28.1 kg/m 2 (IQR 23.6 e 32.6), and 43% were obese. Of these patients, 6 (13%) chose diagnostic testing, 38 (82.7%) opted for a repeat blood draw, and 2 (4.3%) declined additional testing. On repeat cfDNA sampling, 15 (39.5%) had a NR result and 23 (60.5%) had a reported result. Maternal age and BMI did not significantly differ in patients with a persistent NR result (p > 0.05); they were more likely to have maternal comorbidities (p ¼ 0.04) and a FF < 4% at time of initial blood draw (p ¼ 0.05). Obtaining a reportable or NR result on redraw did not differ by laboratory or testing method (p > 0.05). Patients with a repeat NR result were significantly more likely to undergo diagnostic testing (66.7% vs 4.3%, p < 0.01), which yielded an aneuploidy result in 20% of patients. Pregnancy outcomes did not significantly differ in patients with a repeat NR result (p > 0.05), detailed in the table. CONCLUSION: Almost half of repeat testing following a NR cfDNA result will again be NR. Repeat NR result is more likely in patients with medical comorbidities and FF < 4% at initial blood draw. It is associated with a 20% incidence of aneuploidy but not associated with an increased risk of adverse pregnancy outcomes. These test characteristics are important to consider when counseling patients on management following an initial NR cfDNA result. 
